Inside Precision Medicine September 11, 2024
The Series A will advance six programs and the computational platform that designs small molecules targeting membrane-bound proteins in active states
Twelve.
That is how many scientists Superluminal Medicines—which, in the beginning of 2022, was just a concept to develop drugs to membrane-bound proteins with multiple conformations computationally—needed to create a drug pipeline that now includes six programs.
“We were running six programs with 12 people, which is really tight—and they’re all [chemists],” Cony D’Cruz, CEO of Superluminal Medicines, told Inside Precision Medicine. “That can happen when you use computation effectively.”
By the end of last year, D’Cruz said that the board could see that we were making significant progress, particularly on their lead program, which sent Superluminal Medicines into...
Today's Sponsors
Today's Sponsor